To illustrate methodological issues, we compared donor vs no-donor to transplant vs no-transplant comparisons in a cohort of 107 patients aged p50 years with adverse karyotype AML in first CR. Adverse karyotypes were defined as À7, del(7q), À5, del(5q), t(9;22), 11q23, 3q26 or complex abnormalities. Mantel --Byar estimations and hematopoietic SCT (HSCT) as a timedependent variable were used to compare transplant vs no-transplant cumulative incidence of relapse (CIR), relapse-free survival (RFS) and OS. In all, 52 patients had a sibling donor, but only 35 of them were transplanted in first CR, whereas 9 patients received HSCT from alternative stem cell sources. Donor-based analysis showed lower CIR in the donor group, not translating in prolonged RFS or OS. Conversely, transplant-based analysis showed that HSCT in the first CR improved the three CIR (multivariate hazard ratio (HR), 0.31; Po0.001), RFS (multivariate HR, 0.57; P ¼ 0.047) and OS (multivariate HR, 0.54; P ¼ 0.03) endpoints. At 5 years, OS was estimated at 33% in transplanted vs 18% in non-transplanted patients. The positive effect of HSCT was more pronounced in patients aged p35 years and/or in those transplanted in the more recent years. These results confirm that HSCT is likely the best curative option in younger patients with adverse karyotype AML.
INTRODUCTION
Until recently, studies aiming to evaluate the benefit of allogeneic hematopoietic SCT (HSCT) in younger patients with AML in the first CR were based on donor vs no-donor analysis, considering biological donor/no-donor allocation as a kind of randomization, at least when dealing with sibling donors. 1 --5 In these studies, the benefit in outcome observed in the donor group was not seen in patients with a favorable karyotype or in those aged more than 35 or 40 years. 5, 6 At that time, HSCT only included sibling donors and myeloablative conditioning. These results have been incorporated in recent AML management guidelines. 7 In the subset of younger patients with adverse karyotype who reach CR, HSCT is thus considered as the best treatment option.
However, a significant proportion of patients with a donor will never receive HSCT in first CR, especially patients with high-risk AML because of early relapse. Furthermore, the expanding use of HLA-matched unrelated donors (MUDs) may lead to a significant proportion of patients receiving MUD-SCT in the no-donor group and thus bias the Mendelian donor/no-donor allocation, as MUDs may not be identified at the time of CR achievement. For these reasons, in the present study, we also used HSCT as a timedependent covariate to evaluate the role of HSCT in patients with adverse karyotype AML. This methodology allows comparing the outcome of patients actually transplanted to non-transplanted patients without the bias caused by the time to transplant, also called guarantee time. 8 The study included 107 adults aged 50 years or less in first CR (CR1) prospectively included in ALFA trials.
MATERIALS AND METHODS Treatments
The ALFA-9000 trial (1990 --1996) , which included 351 patients aged 50 years or less, has been already reported in detail. 9 Briefly, all patients were randomized between three induction groups: a standard 7 þ 3 induction using high-dose DNR (80 mg/m 2 per d), a day 1/day 20 double induction or a day 1/day 8 timed-sequential induction (TSI) in which a second course of mitoxantrone (MTZ) þ intermediate-dose cytarabine (AraC) was systematically given at day 20 or day 8, respectively. All CR patients then received a mild consolidation course comprising amsacrine for 1 day and standarddose AraC for 5 days, followed by HSCT or a second TSI consolidation course comprising mitoxantrone, intermediate-dose AraC and etoposide (EMA regimen). The subsequent ALFA-9802 trial (1999 --2006; NCT00880243), which included 459 patients aged 50 years or less, has also been previously reported. 10 Briefly, all patients received the TSI according to the ALFA-9000 TSI arm. All the CR patients not eligible for HSCT in first CR were then randomized between the previous ALFA-9000 and the Cancer and Leukemia Group B (CALGB) post-remission therapy containing four cycles of high-dose AraC (HDAC) followed by four maintenance cycles. In both trials, CR was defined according to the International Working Group criteria, 11 and those patients not achieving CR after the planned induction may receive an additional HDAC-based salvage course. Patients with acute promyelocytic leukemia were not included. Unfavorable cytogenetics was defined as À7, del(7q), À5, del(5q), t(9;22), 11q23 or 3q26 abnormalities, and complex karyotypes (Xthree anomalies), according to standard ISCN criteria. 12 All patients with adverse karyotype AML were eligible for myeloablative conditioning-HSCT in first CR if a sibling donor was available. In the 9802 trial, 10/10 HLA-allele MUDs were also considered for patients aged less than 35 years. In all centers, HLA typing and search for a donor started from AML diagnosis. Overall, post-CR treatment was thus HSCT-based, EMA-based or HDAC-based. Studies were approved by the ethics committees of the participating institutions and conducted in accordance with the Declaration of Helsinki. All patients gave written informed consent.
Statistical methods
Main endpoints were OS from CR, relapse-free survival (RFS) and cumulative incidence of relapse (CIR) estimations taking into account deaths in first CR as competing risk. We first performed a classical donor vs no-donor analysis. We then performed a time-dependent transplant vs no-transplant analysis, outcome data being estimated by the Mantel --Byar method, which basically considers HSCT as a time-dependent covariate. 13 Briefly, at the time of first CR achievement, all patients entered initially the no-transplant risk cohort. Each patient transplanted in first CR was then censored from the no-transplant risk cohort at time of HSCT to enter the transplant risk cohort. This time-dependent methodology allowed avoiding the bias caused by the time to transplant also called guarantee time. 8 Outcome comparisons were performed by the Cox model. 14 The following covariates entered the model: trial, need for salvage course to reach first CR, age as a continuous variable and post-CR treatment as two dummy variables (HSCT or not as a time-dependent variable; HDAC-based consolidation or not). To account for age effect and lower HSCT-related mortality reported in the recent times, 15 HSCT/age and HSCT/year interaction terms were also introduced in multivariate models using median age and median HSCT year cutoff, respectively. Type 1 error was fixed at the 5% level. All tests were two-tailed. Hazard ratios (HRs) were given with 95% confidence interval (CI). Statistical analysis was performed on the STATA/SE 10.0 (StataCorp, College Station, TX, USA) software package.
RESULTS

Patients
Among 40 ALFA-9000 patients aged 50 years or less with adverse karyotype AML, 22 reached CR (55%) with 11 induction deaths and 7 primary refractory diseases. Among 98 ALFA-9802 patients with adverse-risk AML, 85 reached CR (87%) with 3 induction deaths and 8 primary refractory diseases. Difference in CR rate might be related to advances made in supportive care with a lower induction mortality rate in the more recent trial. Overall, 18 patients needed an additional salvage course planned by the protocol to reach first CR (late CR, 3 and 15 patients in the 9000 and 9802 study, respectively). Among these 107 patients in first CR, 52 patients had an identified sibling donor identified at time of CR achievement. A total of 44 patients were actually transplanted in first CR (41%), from 35 siblings, 7 MUD and 2 cord blood transplantation. The median transplant year was 2002. The median time from CR to HSCT was 77 days (range, 18 --275). As shown in Table 1 , patients characteristics were well balanced between transplant and no-transplant cohorts. Overall, the median age was 37 years and 49 patients had a complex karyotypes. Most patients had achieved CR after the ALFA TSI. However, the rate of late CR patients was higher in the transplant cohort (27 vs 10%, P ¼ 0.02). In the no-transplant cohort, the main reason for no transplantation in first CR was early relapse before HSCT or before finding an unrelated donor in 26 patients, lack of donor in 21 patients and poor status or physician's choice in 16 patients. Among these 63 non-transplanted patients, 19 ALFA-9802 patients were randomized to receive HDAC-based consolidation. The median followup was 5.4 years.
Donor vs no-donor analysis
A classical donor vs no-donor analysis was performed, based on sibling donor availability at CR achievement time. The nine patients from the ALFA-9802 trial who received non-sibling HSCT in first CR were thus included in the no-donor group. Results of multivariate analyses for CIR, RFS and OS from CR are indicated in Table 2 . Availability of a sibling donor was only predictive of a lower CIR (HR, 0.56; P ¼ 0.03), but had no significant impact on RFS and OS from CR, even when the nine patients who received nonsibling HSCT in first CR were removed from the comparison or censored from both cohorts at transplant time (not shown).
Transplant vs no-transplant analysis
In multivariate analysis, differences in Mantel --Byar estimations reached statistical significance in favor of the transplant risk cohort for the three CIR, RFS and OS from CR endpoints ( Table 3) . As indicated, HSCT in CR1 predicted lower CIR, longer RFS and longer OS from CR (HR, 0.31, 0.57 and 0.54; P ¼ o0.001, 0.047 and 0.03, respectively). Outcome estimations are given in the legend to Figure 1 . Similar results were found when patients who received non-sibling HSCT in first CR were removed from the comparison or censored from both risk cohorts at transplant time (not shown). Of note, at the median time of HSCT, CIR already reached 21% (95%CI, 14 --31) in the no-transplant risk cohort.
When a HSCT/age interaction term was introduced in the model, it appeared that HSCT mostly benefited to patients aged 10 patients did not receive the first planned post-remission treatment, due to poor condition (N ¼ 9) or very early relapse (N ¼ 1); other patients received the first planned post-remission cycle according to their trials. 9, 10 35 years or less for RFS (HR, 0.22; 95% CI, 9 --55; P ¼ 0.001) and OS from CR (HR, 0.38; 95% CI, 0.15 --0.92; P ¼ 0.03), but not to older patients. Interestingly, when a HSCT/year interaction term was introduced in the model, it also appeared that HSCT benefited markedly to patients allografted in the more recent years for RFS (HR, 0.28; 95% CI, 12 --64; P ¼ 0.003) and OS from CR (HR, 0.37; 95% CI, 0.16 --0.84; P ¼ 0.018), rather than to those allografted before 2002. The HSCT/year interaction was independent from the HSCT/ age interaction and related to lower transplant-related mortality in the recent years, as no interaction was observed for the CIR endpoint.
Too few patients received HSCT from an alternative donor to compare the various stem cell sources. In the 35 sibling HSCT patients, 14 relapses and 9 deaths in CR1 were observed. In the nine non-sibling HSCT patients, five relapses and two deaths in CR1 were observed. All deaths in CR1 were transplant related.
As patients who were not transplanted due to poor general health condition after CR1 induction might lower estimations in non-transplanted patients, we repeated the time-dependent HSCT analysis after excluding the 10 patients who never started the first planned post-remission chemotherapy cycle, due to poor condition (N ¼ 9) or very early relapse (N ¼ 1). As shown in Table 4 , results were relatively unchanged with very similar HRs in favor of HSCT as compared to Table 3 , even if the P value for RFS was 0.065 only.
HSCT after relapse Finally, among the 56 patients who relapsed without prior HSCT, 18 patients eventually received allogeneic HSCT after relapse, including 12 siblings, 5 cord blood and 1 MUD transplantations. In these 18 patients, median duration of first CR was 82 days (range, 20 --504) and median time from relapse to HSCT was 98 days (range, 0 --225). At HSCT time, 12 were in second CR, 1 in third CR, whereas 5 had refractory AML at HSCT time. At 5 years, OS from relapse was estimated at 11% (95% CI, 2 --28) in patients who received HSCT after relapse and 4% (95% CI, 0 --15) in those who did not (P ¼ 0.98).
DISCUSSION
The indication for early allogeneic HSCT in patients who have reached first CR is among the crucial decisions the physician dealing with AML patients has to take, given potential benefit/risk implications for each individual patient. Effect of HSCT is, however, not easy to evaluate, especially in patient subsets. First, the optimal methodology to properly compare transplanted to nontransplanted patients remains an open issue, as prospective randomized trials are not easily feasible in this setting. The most commonly proposed method is to perform donor vs no-donor comparisons that may remedy the lack of randomization thought biological treatment assignment. This method remains probably adequate to evaluate HSCT in patients with favorable-or intermediate-risk AML, those with a low rate of early relapse before transplant. It may not be the case for higher-risk AML patients, as a higher proportion of them will early relapse, and therefore are unlikely to be transplanted in first CR or even later on, despite an identified donor. These early events will nevertheless be recorded in the donor group. Another limitation of the donor vs no-donor method became apparent with the expanding use of MUDs, as MUDs are frequently not yet identified at the donor/no-donor allocation time, which is ideally the date of first CR.
Methods allowing evaluation of transplant vs no-transplant cohorts are thus needed. To deal with the guarantee time to transplant issue, several methods have been proposed. The first could be to consider only transplanted patients from the donor group and to withdraw from the no-donor group a subset of matched patients corresponding to those who had a donor but were not transplanted. 5 Propensity score for not being transplanted in the donor group could be used for matching, but which variables should be included to build the propensity score remains an open issue, some of the factors governing HSCT remaining partly uncontrolled. Landmark comparison is another method, but still associated with important limitations in the HSCT setting. How to determine the clinically relevant landmark time when the time to transplant range is so wide (18 --275 days in the present study)? More problematic is the bias introduced by the landmark selection assuming that transplant-related deaths occur earlier in the transplant group than relapse-related deaths in the no-transplant group. The third method is to consider HSCT as a time-dependent variable, as done in the present study. It should be noted, however, that the last two methods are favor the transplant cohort. Actually, patients who were not transplanted due to poor general health condition after CR1 induction might lower outcome estimations in non-transplanted patients. In addition, when estimating OS, patients who experienced very early relapse might also lower further OS estimation in the notransplant risk cohort. 16 That was the reason why we repeated the time-dependent HSCT analysis after excluding patients who never started the first planned post-remission chemotherapy cycle. One may also use the Mantel --Byar approach in the context of donor vs no-donor analysis, with all patients starting in the no-donor risk cohort and then right censored from this cohort and left censored into the donor risk cohort at the time a donor is identified. 17 This last method takes into account the time needed to identify a donor, but not the time to transplant.
We show here that results of donor vs no-donor and transplant vs no-transplant comparisons may differ, especially in patients at high risk of early relapse, like those with adverse karyotype AML. The discrepancy observed between both comparisons may be more visible here, partly due to a high 70% CR rate observed in these high-risk patients with reinforced ALFA induction regimen. It has been suggested that intensified induction might only push into 'cosmetic' CR some very high-risk patients likely to experience very early relapse. Given the high rate of early relapse and the poor results of HSCT after relapse, these patients should be transplanted as soon as possible after CR. Sequential HSCT conditioning could thus be a good option to be studied prospectively. 18 Our transplant vs no-transplant study confirms that better outcomes are associated with HSCT in patients with adverse karyotype AML in first CR. The recently published British Medical Research Council AML12 trial was also analyzed using both donor vs no-donor and Mantel --Byar comparisons. 19 No significant difference in either relapse risk, RFS or OS was found for patients with adverse cytogenetics in donor vs no-donor analysis. However, HSCT significantly improved RFS and OS in adverse karyotype AML patients younger than age 45 years with Mantel --Byar analysis. Another recent study from the German-Austrian group used landmark and multivariate analysis with HSCT as a time-dependent variable in high-risk AML patients, but mainly in those with no response to induction therapy. 20 Finally, we would like to comment on continuous advances made in care procedures and results. This is an important issue, as things are moving more rapidly than clinical trials themselves. Between initiation and final analysis of a trial, factors as important as supportive care, donor type, donor search efficacy, conditioning regimens that now include reduced intensity conditioning and graft-vs-host disease prophylaxis may have evolved. For instance, we show here that the positive HSCT effect is more pronounced in recent years, even in these very high-risk patients, which is very encouraging. This time-period issue is becoming even more important, as widespread AML heterogeneity and discovery of new risk-associated biomarkers both lead us to evaluate the effect of any new or old treatment, including HSCT, within always smaller specific patient subsets. International collaborations are thus strongly warranted. 
